These people may see confusion, changes in behaviour, slurred speech, clumsy movements, blurry or double vision, loss of consciousness, seizures, coma, and even death
Still, not every patient finds Rybelsus to be their ultimate Script savior
The trials cover obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH)
Scientists are looking into how glucagon-related signalling might help burn fat and use energy when paired with GLP-1 and GIP activity
2 Less common but significantly more severe side effects have been documented, including gastroparesis, pancreatitis, kidney complications, the development of arthritis, vision loss and possibly even thyroid cancer
Media Contact: Michael ODonnell D S Simon Media 212-736-2727 [email protected] A video accompanying this announcement is available at